New possibilities for potentiating the effects of antidepressants of the group of selective serotonin reuptake inhibitors by the regulatory peptide Selank in the treatment of anxiety and depressive disorders

DOI: https://doi.org/10.29296/25877305-2019-10-16
Download full text PDF
Issue: 
10
Year: 
2019

Professor V. Verbenko, MD; T. Shakina S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University, Simferopol

The objective of the investigation was to study the abilities of Selank, a synthesized analogue of the endogenous immunity regulator taftcin, to augment the treatment of anxiety and depressive disorders in the first two weeks of taking the antidepressant (enhancement of the efficacy of the antidepressant of the group of selective serotonin reuptake inhibitors).
Keywords: 
adjunctive therapy strategy
regulatory peptides
Selank
anxiety
depression
psychopharmacotherapy

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Washington, DC: American Psychiatric Association; 2010. URL: http://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485
  2. Thase M. Translating Clinical Science Into Effective Therapies // J. Clin. Psychiatry. – 2014; 75 (5): e11. DOI: 10.4088/JCP.13048tx1c.
  3. Ivanets N.N., Kinkul'kina M.A., Avdeeva T.I. i dr. Povyshenie effektivnosti psihofarmakoterapii pozdnih depressij: kombinatsija i zamena antidepressantov // Zhurnal nevrologii i psihiatrii. – 2016; 116 (2): 43–51 [Ivanets N.N., Kinkulkina M.A., Avdeeva T.I. et al. An increase in the efficacy of psychopharmacotherapy of late-onset depressions: combination and substitution of antidepressants // S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2016; 116 (5): 43–51 (in Russ.)]. DOI: 10.17116/jnevro20161165143-51.
  4. The President’s New Freedom Commission on Mental Health. Achieving the Promise: Transforming Mental Health Care in America, Final Report. Rockville, MD: US Department of Health and Human Services: 2003. USDHHS Publication No.SMA-03-3832. URL: http://store.samhsa.gov/product/Achieving-the-Promise-Transforming-Mental-Health-Care-in-America-Executive-Summary/SMA03-3831.
  5. Montgomery S. Is there a role for switching antidepressants in treatment-resistant depression? In: Kasper S., Montgomery M., eds. Treatment-Resistant Depression. 1st ed. / Hoboken, NJ: Wiley-Blackwell, 2013.
  6. Licht R., Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomised study of extended duration of treatment, dose increase or mianserin augmentation // Psychopharmacology (Berl). – 2002; 161 (2): 143–51.
  7. Schweizer E., Rynn M., Mandos L. et al. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial // Int. Clin. Psychopharmacol. – 2001; 16 (3): 137–43.
  8. Papakostas G., Fava M., Thase M. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches // Biol. Psychiatry. – 2008; 63 (7): 699–704.
  9. Souery D., Serretti A., Calati R. et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression // J. Clin. Psychopharmacol. – 2011; 31 (4): 512–6.
  10. Haubmann R., Bauer M. Lithium, thyroid hormones and further augmentation strategies in treatment-resistant depression. In: Kasper S., Montgomery M., eds. Treatment-Resistant Depression. 1st ed. / Hoboken, NJ: Wiley-Blackwell, 2013.
  11. Trivedi M., Fava M., Wisniewski S. et al. STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression // N. Engl. J. Med. – 2006; 354 (12): 1243–52.
  12. Nelson J., Papakostas G. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials // Am. J. Psychiatry. – 2009; 166 (9): 980–91.
  13. Kasper S., Akimova E. The role of atypical antipsychotics in inadequate response and treatment-resistant depression. In: Kasper S., Montgomery M., eds. Treatment-Resistant Depression. 1st ed. / Hoboken, NJ: Wiley-Blackwell, 2013.
  14. Nutt D., Demyttenaere K., Janka Z. et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure // J. Psychopharmacol. – 2007; 21 (5): 461–71.
  15. Pehrson A., Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction // CNS Spectr. – 2013; 1: 1–13.
  16. Fabbri C., Porcelli S., Serretti A. Genetics of treatment-resistant depression. In: Kasper S., Montgomery M., eds. Treatment-Resistant Depression. 1st ed. / Hoboken, NJ: Wiley-Blackwell, 2013.
  17. Zarate C., Duman R., Liu G. et al. New paradigms for treatment-resistant depression // Ann. NY Acad. Sci. – 2013; 1292 (1): 21–31.
  18. Mjasoedov N.F., Illarioshkin S.N., Zhuravleva E.Ju. i dr. Peptidnaja nejroprotektsija preparatom «Selank, kapli nazal'nye 0,15%» u patsientov na rannej stadii s bolezn'ju Parkinsona // Vestn. nevrol., psihiat. i nejrohir. – 2013; 6: 86–95 [Myasoedov N.F., Illarioshkin S.N., Zhuravleva E.Y. et al. Peptide preparation neuroprotection «Selank – 0,15% a nasal drop solution» patients with Parkinson’’s disease at an early stage // Vestn. nevrol., psikhiat. i neirokhir. – 2013; 6: 86–95 (in Russ.)].
  19. Verbenko G., Verbenko V. The effectiveness of selank in the treatment of adjustment disorder // Psychosomatic Medicine and General Practice. – 2018; 3 (1). DOI: 10.26766/pmgp.v3i1.86.
  20. Verbenko V.A. Effektivnost' analoga endogennogo peptida tafttsina pri terapii rasstrojstv pischevogo povedenija // Lechenie i profilaktika. – 2017; 3: 49–57 [Verbenko V.A. Efficacy of peptide anxiolytic Selank in pharmacological treatments for binge eating disorder // Lechenie i profilaktika. – 2017; 3: 49–57 (in Russ.)].
  21. Zozulja A.A., Neznamov G.G., Sjunjakov T.S. i dr. Effektivnost' i vozmozhnye mehanizmy dejstvija novogo peptidnogo anksiolitika Selanka pri terapii generalizovannogo trevozhnogo rasstrojstva i nevrastenii // Zhurn. nevrologii i psihiatrii im. S.S. Korsakova. – 2008; 108 (4): 38–49 [Zozulya A.A., Neznamov G.G., Syunyakov T.S. i dr. Effektivnost’ i vozmozhnye mekhanizmy deistviya novogo peptidnogo anksiolitika Selanka pri terapii generalizovannogo trevozhnogo rasstroistva i nevrastenii // Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. – 2008; 108 (4): 38–49 (in Russ.)].